Amgen Inc. $(AMGN)$ has announced the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide), a long-acting, peptide-antibody conjugate administered subcutaneously on a monthly or less frequent basis. These results, along with complete data from the Phase 1 pharmacokinetics low dose initiation study, were presented at the 85th American Diabetes Association Scientific Sessions and published in The New England Journal of Medicine. The findings have informed the ongoing Phase 3 MARITIME program, which will evaluate the safety, efficacy, and tolerability of MariTide for chronic weight management in individuals with obesity or overweight, with and without Type 2 diabetes. The program includes a 72-week study with participants receiving escalating doses. Additionally, Amgen plans to initiate Phase 3 clinical outcomes studies for atherosclerotic cardiovascular disease, heart failure, and obstructive sleep apnea in 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.